Natco Pharma Reports 36% Drop in Q4 FY26 Revenue, Profit Declines 33%

Natco Pharma's total revenue for the fourth quarter ended March 31, 2026, fell by 36% to ₹816.9 crore, down from ₹1,287.3 crore in the same period last year. Net profit also declined by 33% to ₹269 crore, compared to ₹406.0 crore in Q4 FY25. For the full fiscal year FY26, revenue was ₹4,375.9 crore, a decrease from ₹4,784.0 crore in FY25.

Reader Takeaway: Export revenue decline pressures profits, but a strong pipeline offers future growth potential.

What just happened

Natco Pharma Limited announced its financial results for the fourth quarter and full fiscal year ending March 31, 2026. The company reported a significant year-over-year decline in both total revenue and net profit for the quarter and the full year. The primary reason for this downturn was a substantial drop in revenue from the 'Formulation - Exports' segment.

Why this matters

The decrease in revenue and profit signals potential challenges in key international markets for Natco Pharma. Investors will scrutinize the reasons behind the export decline and the company's strategies to mitigate these headwinds. The reported net profit for Q4 FY26 includes a one-time tax benefit, which investors should consider when evaluating the company's underlying operational performance.

The backstory

Natco Pharma has historically relied on its strong export business, particularly in the United States, for growth. The company has a robust pipeline of Abbreviated New Drug Applications (ANDAs) and is known for its strategic filings for niche products. The Crop Health Sciences segment has been a growing area for the company, showing significant progress in recent years.

What changes now

Following this results announcement, investors will likely assess the sustainability of the company's performance. The focus will be on management's commentary regarding the export market dynamics, any new strategies to revive export growth, and the progress of its domestic and Crop Health Sciences businesses. The company's investments in NCE and gene therapy assets, along with its Para IV filings pipeline, remain crucial for future prospects.

Risks to watch

The primary risk highlighted is the sharp contraction in export formulation revenue. This indicates potential increased competition, pricing pressures, or regulatory challenges in key overseas markets. The reliance on one-time benefits to support profitability in a quarter also presents a watch point.

Peer comparison

While specific peer comparisons are not provided in the filing, Natco Pharma operates in a competitive pharmaceutical landscape. Companies like Divi's Laboratories, Laurus Labs, and Aurobindo Pharma also have significant export-oriented businesses and face similar market dynamics. The performance of these peers in their latest results will offer a broader industry perspective.

Context metrics (time-bound)

• Q4 FY26 Total Revenue: ₹816.9 crore (down 36% YoY)
• FY26 Total Revenue: ₹4,375.9 crore (down 8.5% YoY)
• Q4 FY26 Net Profit: ₹269 crore (down 33% YoY)
• FY26 Net Profit: ₹1,418.5 crore (down 24.7% YoY)
• Export Formulation Revenue (Q4 FY26): ₹539.6 crore (down from ₹1,052.5 crore in Q4 FY25)
• Crop Health Sciences Revenue (FY26): ₹138.2 crore (up from ₹59.8 crore in FY25)

What to track next

Investors will be keen to monitor the company's upcoming quarterly results to see if the export revenue decline is a temporary setback or a sustained trend. Progress on its pipeline of 28 Para IV filings, particularly the 20+ FTFs, and the performance of its domestic formulations and Crop Health Sciences segments will be key indicators to track.